Who are A. Paniculata and A. Chilensis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): herbal immunomodulator, Lamivudine+Oxymatrine Capsules, Comarum Palustre, LingZhi capsule, Dendrobium Huoshanense Suppository, Umckamin syrup.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/a-paniculata-and-a-chilensis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

A. Paniculata and A. Chilensis — Competitive Intelligence Brief

A. Paniculata and A. Chilensis (A. Paniculata and A. Chilensis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal immunomodulator. Area: Immunology / Inflammation.

phase 3 Herbal immunomodulator Immunology / Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

A. Paniculata and A. Chilensis (A. Paniculata and A. Chilensis) — Vedic Lifesciences Pvt. Ltd.. A herbal combination derived from Andrographis paniculata and Andrographis chilensis that modulates immune function and reduces inflammation through multiple phytochemical constituents.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
A. Paniculata and A. Chilensis TARGET	A. Paniculata and A. Chilensis	Vedic Lifesciences Pvt. Ltd.	phase 3	Herbal immunomodulator
herbal immunomodulator	herbal immunomodulator	Tatyasaheb Kore Dental College	marketed	Herbal immunomodulator
Lamivudine+Oxymatrine Capsules	Lamivudine+Oxymatrine Capsules	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor + herbal immunomodulator	Reverse transcriptase; oxymatrine targets multiple immune pathways (non-specific)
Comarum Palustre	Comarum Palustre	Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology	marketed	herbal immunomodulator
LingZhi capsule	LingZhi capsule	The University of Hong Kong	phase 3	Herbal immunomodulator
Dendrobium Huoshanense Suppository	Dendrobium Huoshanense Suppository	Zhejiang Cancer Hospital	phase 3	Herbal immunomodulator
Umckamin syrup	Umckamin syrup	Korea United Pharm. Inc.	phase 3	Herbal immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal immunomodulator class)

Korea United Pharm. Inc. · 1 drug in this class
Tatyasaheb Kore Dental College · 1 drug in this class
The University of Hong Kong · 1 drug in this class
Vedic Lifesciences Pvt. Ltd. · 1 drug in this class
Zhejiang Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). A. Paniculata and A. Chilensis — Competitive Intelligence Brief. https://druglandscape.com/ci/a-paniculata-and-a-chilensis. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab